MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer

PURPOSE: PI3K-pathway activation occurs in concomitance with RAS/BRAF mutations in colorectal cancer (CRC) limiting the sensitivity to targeted therapies. Several clinical studies are being conducted to test the tolerability and clinical activity of dual MEK and PI3K-pathway blockade in solid tumors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: García-García, Celina, Rivas, Martín A., Ibrahim, Yasir H., Calvo, María Teresa, Gris-Oliver, Albert, Rodríguez, Olga, Grueso, Judit, Antón, Pilar, Guzmán, Marta, Aura, Claudia, Nuciforo, Paolo, Jessen, Katti, Argilés, Guillem, Dienstmann, Rodrigo, Bertotti, Andrea, Trusolino, Livio, Matito, Judit, Vivancos, Ana, Chicote, Irene, Palmer, Héctor G., Tabernero, Josep, Scaltriti, Maurizio, Baselga, José, Serra, Violeta
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087596/
https://ncbi.nlm.nih.gov/pubmed/26272063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados